Skip to main contentAll experts

Burak Zeybek

CLIN AST PROF

MD-OBSTETRICS - GYNECOLOGY

Orcid identifier0000-0003-4146-8614 (opens in a new tab)⁠
  • CLIN AST PROF
    MD-OBSTETRICS - GYNECOLOGY

GRANTS

  • GRANT
    A Randomised, Open-label, Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine in FRa-high and AZD5335 Versus Investigator's Choice Chemotherapy in FRa-low Expressing High-grade Platinum-resistant Epithelial Ovarian Cancer Patients (TREVI-OC-01)
    Astrazeneca Pharm1 Jul 2026 - 30 Jun 2031
    Active